$PPCBOct 7, 2026, 8:31 AM ETAI processed
PPCB: PRP shows >90% tumor growth inhibition and >2.5x survival in preclinical pancreatic cancer; Phase 1b planned Q1 2027
AI Summary
Propanc reported preclinical PRP data showing >90% mean tumor growth inhibition vs vehicle in orthotopic and patient-derived PDAC models (p<0.001), with marked reductions in liver/peritoneal metastases, tumor microenvironment remodeling (less fibrosis/EMT, lower CAF activity) and chemosensitization; median overall survival in animals increased >2.5-fold. The company says PRP (an IV trypsinogen+chymotrypsinogen combo, not a RAS inhibitor) holds FDA orphan status, is genotype-agnostic, and will enter a multicenter open-label Phase 1b first-in-human study in Q1 2027 (up to 50 advanced solid-tumor patients); Propanc positions PRP as a complementary approach to Revolution Medicines' recently FDA-approved daraxonrasib.
Positives
- >90% mean tumor growth inhibition in orthotopic and PDX PDAC models (p<0.001)
- >2.5-fold median overall survival extension in treated animal models
- Preclinical effects include reduced metastases, reduced fibrosis/EMT markers, and increased chemosensitivity
Negatives
- All efficacy data reported are preclinical; human efficacy and safety are unproven
- Planned Phase 1b is small (up to 50 patients) and early-stage (open-label)
- PRP does not target RAS, so it would not replace RAS-directed therapies and may require combination testing